MTOR and acute lymphoblastic leukemia: Combined targeting of CDK and mTOR is being studied in a phase 1 trial of Ribociclib with Everolimus and DEX in patients ages 1–30 years with relapsed/refractory B and T-ALL (NCT03740334).